Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised
about
Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins.[Factor XIII : Pharmacodynamic and pharmacokinetic characteristics].
P2860
Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-Sectional Guidelines for ...... pter 5 Human Albumin - Revised
@en
Cross-Sectional Guidelines for ...... ter 5 Human Albumin - Revised.
@nl
type
label
Cross-Sectional Guidelines for ...... pter 5 Human Albumin - Revised
@en
Cross-Sectional Guidelines for ...... ter 5 Human Albumin - Revised.
@nl
prefLabel
Cross-Sectional Guidelines for ...... pter 5 Human Albumin - Revised
@en
Cross-Sectional Guidelines for ...... ter 5 Human Albumin - Revised.
@nl
P2860
P356
P1476
Cross-Sectional Guidelines for ...... pter 5 Human Albumin - Revised
@en
P2093
Executive Committee of the Ger ...... the Scientific Advisory Board
P2860
P304
P356
10.1159/000446043
P577
2016-05-03T00:00:00Z